PL3071230T3 - Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania - Google Patents

Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania

Info

Publication number
PL3071230T3
PL3071230T3 PL14812084T PL14812084T PL3071230T3 PL 3071230 T3 PL3071230 T3 PL 3071230T3 PL 14812084 T PL14812084 T PL 14812084T PL 14812084 T PL14812084 T PL 14812084T PL 3071230 T3 PL3071230 T3 PL 3071230T3
Authority
PL
Poland
Prior art keywords
compositions
treatment
methods
same
rheumatoid arthritis
Prior art date
Application number
PL14812084T
Other languages
English (en)
Polish (pl)
Inventor
Xiaohong Huang
Martine JASSON
Vanessa MARKS
Allen Radin
Chungpeng FAN
Hubert VAN HOOGSTRATEN
Stefano FIORE
Janet VAN ADELSBERG
Mark Genovese
Original Assignee
Sanofi Biotechnology
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc. filed Critical Sanofi Biotechnology
Publication of PL3071230T3 publication Critical patent/PL3071230T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14812084T 2013-11-22 2014-11-21 Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania PL3071230T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US201462008787P 2014-06-06 2014-06-06
EP14306366 2014-09-05
PCT/US2014/066856 WO2015077582A1 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same
EP14812084.3A EP3071230B1 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same

Publications (1)

Publication Number Publication Date
PL3071230T3 true PL3071230T3 (pl) 2020-09-21

Family

ID=51518724

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14812084T PL3071230T3 (pl) 2013-11-22 2014-11-21 Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania

Country Status (11)

Country Link
US (1) US20160280782A1 (enExample)
EP (2) EP3071230B1 (enExample)
JP (4) JP6657089B2 (enExample)
KR (4) KR20230155586A (enExample)
CN (2) CN106413748A (enExample)
AU (3) AU2014352801B2 (enExample)
CA (1) CA2930615C (enExample)
MX (2) MX377190B (enExample)
PL (1) PL3071230T3 (enExample)
SG (1) SG10201804000TA (enExample)
WO (1) WO2015077582A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
KR20230155586A (ko) * 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
KR20230093522A (ko) * 2016-03-07 2023-06-27 사노피 바이오테크놀로지 류마티스 관절염의 치료를 위한 조성물 및 방법
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
KR102871642B1 (ko) 2017-12-07 2025-10-15 자크로스 가부시키가이샤 포트가 부착된 백 및 캡이 부착된 백
KR20260109977A (ko) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
JP7542543B2 (ja) * 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP2022545312A (ja) * 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) * 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP7373958B2 (ja) 2019-09-27 2023-11-06 株式会社日立製作所 分析システム及び分析方法
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대
US12254347B2 (en) * 2021-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Data pipeline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
PT3071230T (pt) * 2013-11-22 2020-06-26 Regeneron Pharma Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas
KR20230155586A (ko) * 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Also Published As

Publication number Publication date
KR20260060447A (ko) 2026-05-04
EP3770173A1 (en) 2021-01-27
MX2020011993A (es) 2021-01-29
CA2930615C (en) 2023-04-04
AU2024204881A1 (en) 2024-08-15
JP2022033891A (ja) 2022-03-02
MX377190B (es) 2025-03-07
KR20230155586A (ko) 2023-11-10
WO2015077582A1 (en) 2015-05-28
KR20160079121A (ko) 2016-07-05
AU2014352801A1 (en) 2016-06-23
JP2024026223A (ja) 2024-02-28
JP6657089B2 (ja) 2020-03-04
EP3071230B1 (en) 2020-04-08
MX2016006595A (es) 2016-09-06
CN106413748A (zh) 2017-02-15
JP2016539125A (ja) 2016-12-15
JP2026032035A (ja) 2026-02-25
AU2020223706B2 (en) 2024-04-18
SG10201804000TA (en) 2018-07-30
KR20220056254A (ko) 2022-05-04
US20160280782A1 (en) 2016-09-29
EP3071230A1 (en) 2016-09-28
CA2930615A1 (en) 2015-05-28
CN120514847A (zh) 2025-08-22
AU2020223706A1 (en) 2020-09-10
AU2014352801B2 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
IL273090B (en) Methods and preparations for the treatment of cancer
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
ZA201701244B (en) Carrier-antibody compositions and methods of making and using the same
IL232001A0 (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
IL265876A (en) Preparations that include 15-ohepa and methods of using them
SG10201708595YA (en) Cenicriviroc compositions and methods of making and using the same
IL247312A0 (en) Preparations of seleno-organic compounds and methods of using them
IL244621A0 (en) Preparations for the treatment of hypertension and/or fibrosis
IL244622A0 (en) Preparations for the treatment of hypertension and/or fibrosis
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
PT3071230T (pt) Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas
IL239812A0 (en) Method and composition for the treatment of arthritis and osteoarthritis
IL286709B1 (en) Preparations for the treatment of rheumatoid arthritis and methods of using them
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same